75293-97-9

Basic information

• Product Name: 2-nitro-4,5-dibromoaniline
• Synonyms: 2-nitro-4,5-dibromoaniline
• CAS NO: 75293-97-9
• Molecular Weight: 295.918
• Mol File: 75293-97-9.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2-nitro-4,5-dibromoaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-nitro-4,5-dibromoaniline(75293-97-9)
• EPA Substance Registry System: 2-nitro-4,5-dibromoaniline(75293-97-9)

Safety Data

• Hazardous Substances Data: 75293-97-9(Hazardous Substances Data)

Upstream product

• 54558-18-8 1,2-dinitro-4,5-dibromobenzene 
• 98-82-8 Isopropylbenzene 
• 610-38-8 4-bromo-1,2-dinitrobenzene 
• 58683-70-8 1,2,4-tribromo-5-isopropyl-benzene 
• 179061-90-6 3,4-dibromo-(trifluoroacetamido)benzene 
• 615-55-4 3,4-dibromoaniline 
• 7664-41-7 ammonia 
• 5228-61-5 5-bromo-2-nitroaniline 
• 7726-95-6 bromine 
• 64-19-7 acetic acid 
• 89365-48-0 1,2,4-tribromo-5-nitrobenzene 
• 75293-96-8 acetic acid-(4,5-dibromo-2-nitro-anilide) 

Downstream Products

• 319916-63-7 5,6-dibromo-2-(3,4-diaminophenyl)benzimidazole 
• 319916-62-6 5,6-dibromo-2-(3,4-dinitrophenyl)benzimidazole 
• 49764-63-8 4,5-dibromo-1,2-diaminobenzene 
• 79319-38-3 5-amino-5-nitrophthalodinitrile 
• 129365-93-1 4,5-diaminophthalonitrile 

Relevant articles and documents

A novel fully conjugated phenanthroline-appended phthalocyanine: Synthesis and characterisation

The synthetic route to a new fully conjugated phenanthroline appended phthalocyanine is described. This compound has been fully characterised by elemental analysis, UV-VIS, IR, MS and 1H NMR spectroscopy.

Glycine receptor antagonists and the use thereof

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.

Salts of dihalo-3,4-dihydro-3-oxo-2-quinoxaline carboxylic acids and hindered amines

Salts of 6,7-dihalo-3,4-dihydro-3-oxo-2-quinoxaline carboxylic acids and hindered amines, useful in combating influenza A and B.